Janssen Robert 4
4 · DYNAVAX TECHNOLOGIES CORP · Filed Feb 18, 2025
Insider Transaction Report
Form 4
Janssen Robert
Chief Medical Officer and VP
Transactions
- Exercise/Conversion
Restricted Stock Unit
2025-02-13−13,000→ 0 total→ Common Stock (13,000 underlying) - Award
Restricted Stock Unit
2025-02-13+33,333→ 33,333 total→ Common Stock (33,333 underlying) - Exercise/Conversion
Common Stock
2025-02-13+13,000→ 74,236 total - Tax Payment
Common Stock
2025-02-13$12.69/sh−4,614$58,552→ 69,622 total - Award
Restricted Stock Unit
2025-02-13+13,000→ 13,000 total→ Common Stock (13,000 underlying) - Award
Stock Options (Right to Buy)
2025-02-13+55,000→ 55,000 totalExercise: $12.69Exp: 2032-02-13→ Common Stock (55,000 underlying)
Footnotes (4)
- [F1]Each RSU represents a contingent right to receive one share of common stock. These RSUs vested upon the Issuer's achievement of a certain performance condition.
- [F2]Shares withheld by Dynavax Technologies Corporation to satisfy tax withholding requirements on vesting of restricted stock units.
- [F3]This option grant will vest over three (3) years with one third (1/3) of the shares subject to the option vesting twelve months after the grant date of February 13, 2025, and one thirty-sixth (1/36) of the shares subject to the option vesting each month thereafter.
- [F4]Each RSU represents a contingent right to receive one share of common stock. The RSUs vest over three years with 1/3 vesting on each annual anniversary of February 13, 2025.